DISCO Pharmaceuticals has entered a research collaboration and option-to-license agreement with AbbVie to develop bispecific therapies for solid tumors. DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in option, development and other milestone payments, bringing the potential payments to $2.54 billion before tiered royalties on worldwide net sales.
The collaboration combines DISCO’s drug discovery platform with AbbVie’s oncology research and development work. DISCO will carry out specified research activities, and if it completes them successfully, AbbVie will have the option to take exclusive licenses to selected programs for further development.
DISCO’s platform, called DISCOtech, maps patterns of protein expression on the surface of cancer cells to identify pairs of targets for drug development. The partners will use that approach to look for target pairs that could help distinguish tumor cells from healthy tissue in solid tumors with limited treatment options.
The proposed therapies use what DISCO calls an AND-gated design, which is intended to engage two targets on a cell at the same time. By requiring both targets, DISCO aims to reduce the risk of affecting healthy cells that carry only one of them, a problem known as on-target, off-tumor toxicity.
DISCO is applying the same dual-target approach across its broader oncology pipeline, which includes antibody-drug conjugates and T-cell engagers. The company said its lead programs for small cell lung cancer and colorectal cancer are advancing toward clinical testing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!